Xiaosu Ma

1.1k total citations · 4 hit papers
22 papers, 670 citations indexed

About

Xiaosu Ma is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Xiaosu Ma has authored 22 papers receiving a total of 670 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Endocrinology, Diabetes and Metabolism, 10 papers in Surgery and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Xiaosu Ma's work include Diabetes Treatment and Management (15 papers), Diabetes Management and Research (7 papers) and Pancreatic function and diabetes (5 papers). Xiaosu Ma is often cited by papers focused on Diabetes Treatment and Management (15 papers), Diabetes Management and Research (7 papers) and Pancreatic function and diabetes (5 papers). Xiaosu Ma collaborates with scholars based in United States, Australia and Singapore. Xiaosu Ma's co-authors include Edward Pratt, Axel Haupt, Deborah A. Robins, Kieren J. Mather, Christof Kazda, Маниге Кониг, Julio Rosenstock, Lisa Connery, Sean Wharton and Rong Liu and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Xiaosu Ma

19 papers receiving 658 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

2023 259 citations Sean Wharton, Thomas Blevins et al. New England Journal of Medicine profile →
Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)

2023 124 citations Steven E. Nissen, Helle Linnebjerg et al. JAMA profile →
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study

2023 97 citations Juan P. Frías, Stanley H. Hsia et al. The Lancet profile →
Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial

2025 16 citations Kausik K. Ray, Robert S. Rosenson et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xiaosu Ma United States	10	451	227	219	169	132	22	670
Ted Okerson United States	11	845 1.9×	479 2.1×	255 1.2×	364 2.2×	89 0.7×	21	1.0k
Ivano Franzetti Italy	14	430 1.0×	177 0.8×	101 0.5×	212 1.3×	54 0.4×	21	604
Günaj Rakipovski Denmark	9	363 0.8×	137 0.6×	78 0.4×	211 1.2×	69 0.5×	15	547
Deborah T. Cirkel United Kingdom	8	463 1.0×	157 0.7×	110 0.5×	221 1.3×	35 0.3×	8	529
Christof Kazda United States	13	836 1.9×	411 1.8×	234 1.1×	290 1.7×	175 1.3×	30	1.0k
Christopher Sorli United States	13	832 1.8×	443 2.0×	286 1.3×	421 2.5×	225 1.7×	28	1.2k
Mario Widel United States	7	764 1.7×	281 1.2×	139 0.6×	430 2.5×	68 0.5×	11	922
Marie‐Louise Hartoft‐Nielsen Denmark	11	439 1.0×	97 0.4×	96 0.4×	237 1.4×	60 0.5×	17	635
Marilyn K. Boardman United States	10	1.0k 2.3×	358 1.6×	275 1.3×	470 2.8×	84 0.6×	12	1.1k
Tadashi Arao Japan	14	301 0.7×	134 0.6×	49 0.2×	97 0.6×	48 0.4×	36	516

Countries citing papers authored by Xiaosu Ma

Since Specialization

Citations

This map shows the geographic impact of Xiaosu Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaosu Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaosu Ma more than expected).

Fields of papers citing papers by Xiaosu Ma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaosu Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaosu Ma. The network helps show where Xiaosu Ma may publish in the future.

Co-authorship network of co-authors of Xiaosu Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaosu Ma. A scholar is included among the top collaborators of Xiaosu Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaosu Ma. Xiaosu Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chigutsa, Emmanuel, et al.. (2025). A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure–Response Relationship during Treatment of Obesity with Tirzepatide. Clinical Pharmacology & Therapeutics. 118(6). 1489–1498.

Ray, Kausik K., Robert S. Rosenson, Jeremiah Jones, et al.. (2025). Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet. 405(10489). 1594–1607. 16 indexed citations breakdown →

Morse, Bridget L., Shobha Bhattachar, Xiaosu Ma, et al.. (2025). Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants. Clinical Pharmacology in Drug Development. 15(1). e1594–e1594. 1 indexed citations

Ray, Kausik K., Helle Linnebjerg, Laura F. Michael, et al.. (2025). Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies. Journal of the American College of Cardiology. 85(19). 1803–1818. 4 indexed citations

Ma, Xiaosu, Rong Liu, Edward Pratt, et al.. (2024). Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Therapy. 15(4). 819–832. 12 indexed citations

Ray, Kausik K., Giacomo Ruotolo, Xi Shen, et al.. (2024). SOLBINSIRAN, A GALNAC-CONJUGATED SIRNA TARGETING ANGPTL3, REDUCES ATHEROGENIC LIPOPROTEINS IN INDIVIDUALS WITH MIXED DYSLIPIDAEMIA IN A DURABLE AND DOSEDEPENDENT MANNER. Journal of the American College of Cardiology. 83(13). 1673–1673. 8 indexed citations

Pratt, Edward, Xiaosu Ma, Rong Liu, et al.. (2023). Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants. Diabetes Obesity and Metabolism. 25(9). 2634–2641. 23 indexed citations

Pratt, Edward, Xiaosu Ma, Rong Liu, et al.. (2023). Orforglipron ( LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes. Diabetes Obesity and Metabolism. 25(9). 2642–2649. 34 indexed citations

Frías, Juan P., Stanley H. Hsia, Rong Liu, et al.. (2023). Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. The Lancet. 402(10400). 472–483. 97 indexed citations breakdown →

10.

Wharton, Sean, Thomas Blevins, Lisa Connery, et al.. (2023). Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. New England Journal of Medicine. 389(10). 877–888. 259 indexed citations breakdown →

11.

Nissen, Steven E., Helle Linnebjerg, Xi Shen, et al.. (2023). Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a). JAMA. 330(21). 2075–2075. 124 indexed citations breakdown →

12.

Urva, Shweta, Tonya Quinlan, John Landry, et al.. (2022). Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clinical Pharmacokinetics. 61(7). 1057–1067. 21 indexed citations

13.

Xing, Yifan, et al.. (2020). Development and Verification of a Body Weight–Directed Disease Trial Model for Glucose Homeostasis. The Journal of Clinical Pharmacology. 61(2). 234–243. 2 indexed citations

14.

Shireman, Laura M., Xiaosu Ma, Danny D. Shen, et al.. (2019). Pharmacodynamics of Metformin in Pregnant Women With Gestational Diabetes Mellitus and Nonpregnant Women With Type 2 Diabetes Mellitus. The Journal of Clinical Pharmacology. 60(4). 540–549. 4 indexed citations

15.

Pratt, Edward, Tomonori Oura, Xiaosu Ma, et al.. (2019). 20-OR: GPR142 Agonists Increase Glucose-Dependent Insulin Secretion and Differentially Regulate Hormone Secretion in Preclinical and Phase 1 Studies. Diabetes. 68(Supplement_1).

16.

Ma, Xiaosu, Jenny Y. Chien, Jennal Johnson, James Malone, & Vikram Sinha. (2017). Simulation-Based Evaluation of Dose-Titration Algorithms for Rapid-Acting Insulin in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antihyperglycemic Medications. Diabetes Technology & Therapeutics. 19(8). 483–490. 2 indexed citations

17.

Mari, Andrea, Julio Rosenstock, Xiaosu Ma, Ying G. Li, & Jeffrey A. Jackson. (2015). Optimized Human Regular U-500 Insulin Treatment Improves β-Cell Function in Severely Insulin-Resistant Patients with Long-Standing Type 2 Diabetes and High Insulin Requirements. Endocrine Practice. 21(12). 1344–1353. 8 indexed citations

18.

Peña, Amparo de la, Xiaosu Ma, Shobha Reddy, et al.. (2014). Application of PK/PD Modeling and Simulation to Dosing Regimen Optimization of High-Dose Human Regular U-500 Insulin. Journal of Diabetes Science and Technology. 8(4). 821–829. 28 indexed citations

19.

Ma, Xiaosu, Dorothy J. Becker, Vincent C. Arena, Paolo Vicini, & Carla J. Greenbaum. (2009). The Effect of Age on Insulin Sensitivity and Insulin Secretion in First-Degree Relatives of Type 1 Diabetic Patients: A Population Analysis. The Journal of Clinical Endocrinology & Metabolism. 94(7). 2446–2451. 17 indexed citations

20.

Hébert, Mary F., Suresh Babu Naraharisetti, Xiaosu Ma, et al.. (2007). 53: Are we guessing glyburide dosage in the treatment of gestational diabetes (GDM)? The pharmacological evidence for better clinical practice. American Journal of Obstetrics and Gynecology. 197(6). S25–S25. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact